Stoke Therapeutics (STOK) Net Cash Flow Growth (3y) (2021 - 2026)
Powered by 
Analysis
Stoke Therapeutics (STOK) Net Cash Flow Growth (3y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | -8.34% |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 36.60% |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | -35.85% |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 106.37% |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 67.39% |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 4.55% |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 52.78% |
| 10 | Stoke Therapeutics | 1.95 Bn | 1.66 Bn | - | -205.56% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -205.56% |
| Mar 31, 2026 | -1.03% |
| Dec 31, 2025 | 72.83% |
| Sep 30, 2025 | -33.84% |
| Jun 30, 2025 | -119.65% |
| Mar 31, 2025 | 64.06% |
| Dec 31, 2024 | -71.94% |
| Sep 30, 2024 | -30.54% |
| Jun 30, 2024 | 29.09% |
| Mar 31, 2024 | 13.39% |
| Dec 31, 2023 | -75.18% |
| Sep 30, 2023 | 41.62% |
| Jun 30, 2023 | 29.74% |
| Mar 31, 2023 | 106.97% |
| Dec 31, 2022 | 26.31% |
| Sep 30, 2022 | 88.89% |
| Jun 30, 2022 | -28.33% |
| Mar 31, 2022 | -108.67% |
| Dec 31, 2021 | -27.03% |
| Sep 30, 2021 | -58.60% |